Farmakoterapia wysokimi dawkami metotreksatu (HDMTX) w onkologii – jak należy prowadzić chemioterapię w oparciu o terapeutyczne monitorowanie stężeniem leku?

Aleksandra Mikulska; Arkadiusz Kocur

doi:10.56782/pps.167

Published : 2023-11-12

Vol. 21 No. 4 (2023)

Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring?

Aleksandra Mikulska

Arkadiusz Kocur

DOI: https://doi.org/10.56782/pps.167

Abstract

Methotrexate (MTX) is a crucial cytostatic drug used both in autoimmune diseases (low doses) and cancer chemotherapy, especially in the lymphatic system (high doses). MTX is a folic acid antagonist with a strong affinity for enzymes involved in the folic pathway. It is a highly toxic drug with documented prevention of side effects using compensatory therapy with leucovorin. High-dose methotrexate (HDMTX) is administered as an intravenous bolus with a body surface area of > 500 mg/m². Because these concentrations are highly toxic, but at the same time, the therapeutic benefits are higher than the compensated side effects, it is necessary to conduct therapeutic drug monitoring. During pharmacotherapy with MTX, routine monitoring of MTX and serum creatinine concentrations is performed, while the dose of leucovorin infusion, with the possible addition of glucarpidase, is adjusted simultaneously.

The aim of this study was a mini-review of the pharmacological properties of MTX, combined with a particular emphasis on the variability in the pharmacokinetics of this drug, justifying the need for therapeutic monitoring of concentrations. HDMTX therapy, clinical recommendations, and therapy methods based on global guidelines are discussed. In addition, the issues of both MTX treatment and salvage treatment with leucovorin and glucarpidase were discussed.

HDMTX treatment should be performed under special supervision following the accepted clinical protocol. Only the appropriate cooperation of the doctor, nursing staff, laboratory diagnosticians, clinical pharmacists, and, most importantly, the patient should allow for effective treatment, with the appropriate reduction of toxic side effects to a minimum.

Keywords:

methotrexate, pharmacokinetics, HDMTX, therapeutic drug monitoring, toxicity, leucovorin

Most read articles by the same author(s)

Arkadiusz Kocur, Dorota Marszałek, Tomasz Pawiński, USE OF CHROMATOGRAPHIC METHODS FOR INOSINE DEHYDROGENASE ACTIVITY DETERMINATION (IMPDH) IN IMMUNOSUPPRESSIVE THERAPY , Prospects in Pharmaceutical Sciences: Vol. 18 No. 5 (2020)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Mikulska, A., & Kocur, A. (2023). Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring?. Prospects in Pharmaceutical Sciences, 21(4), 40–47. https://doi.org/10.56782/pps.167

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

DrugBank: a comprehensive resource for in silico drug discovery and exploration. Dostęp online: https://go.drugbank.com/drugs/DB00563 (data dostępu 20-08-2023)

FDA Approved Drug Products: Methotrexate Sodium Oral Tablets. Dostęp online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf (data dostępu 20-08-2023)

Bouquié, R.; Deslandes, G.; Nieto, B.; Renaud, C.; Dailly, E.; Jolliet, P. A fast LC-MS/MS assay for methotrexate monitoring in plasma: validation, comparison to FPIA and application in the setting of carboxypeptidase therapy. Anal. Methods UK 2014, 6(1), 178–186. doi.10.1039/c3ay40815a DOI: https://doi.org/10.1039/C3AY40815A

Inoue, K.; Yuasa, H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab. Pharmacokinet. 2014, 29(1), 12-9. doi.10.2133/dmpk.dmpk-13-rv-119. DOI: https://doi.org/10.2133/dmpk.DMPK-13-RV-119

Song, Z.; Hu, Y.; Liu, S.; Wang, G.; Zhai, S.; Zhang, X.; Li, Y.; Du, G.; Shi, Y.; Chen, Y.; Dong, M.; Guo, R.; Guo, W.; Huang, H.; Huang, X.; Jing, H.; Ke, X.; Li, G.; Miao, L.; Niu, X.; Qiu, F.; Shen, J.; Tang, J.; Wang, T.; Wang, X.; Wang, Z.; Wu, J.; Zhan, S.; Zhang, B.; Zhang, L.; Zhang, Y.; Zhang, W.; Zhao, L.; Zhao, L.; Zhen, J.; Zheng, H.; Zhu, Z.; Jiang, D.; Huang, Z.; Tan, Z.; Lin, Q.; Zhao, R. Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Br. J. Clin. Pharmacol. 2022, 88(5), 2456-2472. doi.10.1111/bcp.15134.

Karami, F.; Ranjbar, S.; Ghasemi, Y.; Negahdaripour, M. Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples. J. Pharm. Anal. 2019, 9(6), 373-391. doi.10.1016/j.jpha.2019.06.001. DOI: https://doi.org/10.1016/j.jpha.2019.06.001

Drugs.com. Methotrexate Monograph for Professionals. Dostęp online: https://www.drugs.com/monograph/methotrexate.html (data dostępu 20-08-2023)

PubChem database. Methotrexate. Dostęp online: https://pubchem.ncbi.nlm.nih.gov/compound/Methotrexate (data dostępu 20-08-2023)

Muller, I.B.; Lin, M.; Struys, E.A.; Heydari, P.; Hebing, R.C.F.; Nurmohamed, M.T.; van der Laken, C.; Lems, W.F.; Cloos, J.; Jansen G.; de Jonge R. Development and Validation of a Sensitive UHPLC-MS/MS-Based Method for the Analysis of Folylpolyglutamate Synthetase Enzymatic Activity in Peripheral Blood Mononuclear Cells: Application in Rheumatoid Arthritis and Leukemia Patients. Ther. Drug Monit. 2019, 41(5), 598-606. doi.10.1097/FTD.0000000000000638. DOI: https://doi.org/10.1097/FTD.0000000000000638

Howard, S.C.; McCormick, J.; Pui, C.H.; Buddington, R.K.; Harvey R.D. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 2016, 21(12), 1471-1482. doi.10.1634/theoncologist.2015-0164. DOI: https://doi.org/10.1634/theoncologist.2015-0164

Thomas, S.; Fisher, K.H.; Snowden, J.A.; Danson, S.J.; Brown, S.; Zeidler M.P. Methotrexate Is a JAK/STAT Pathway Inhibitor. PLoS One. 2015, 10(7), Art. No: e0130078. doi.10.1371/journal.pone.0130078. DOI: https://doi.org/10.1371/journal.pone.0130078

Smita, P.; Narayan, P.A.; Gaurav, P. Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. Front. Oncol. 2022, 12, Art. No:1015200. doi.10.3389/fonc.2022.1015200. DOI: https://doi.org/10.3389/fonc.2022.1015200

Mei, S.; Shi, X.; Du, Y.; Cui, Y.; Zeng, C.; Ren, X.; Yu, K.; Zhao, Z.; Lin, S. Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC-MS/MS in patients receiving high-dose methotrexate therapy. J. Pharm. Biomed. Anal. 2018, 158, 300-306. Doi.10.1016/j.jpba.2018.06.011. DOI: https://doi.org/10.1016/j.jpba.2018.06.011

Kodidela, S.; Suresh Chandra, P.; Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur. J. Clin. Pharmacol. 2014, 70(3), 253-60. doi.10.1007/s00228-013-1623-4. 24370659. DOI: https://doi.org/10.1007/s00228-013-1623-4

Szpak, E.; Lewandowski, K.; Kowalski, R.; Bogomas-Woźnicka, B.; Irga-Jaworska, N. Znaczenie farmakoterapii monitorowanej w chemioterapii z użyciem metotreksatu. Diagnostyka Laboratoryjna 2017, 53(4), 241-246. DOI: https://doi.org/10.5604/01.3001.0013.7991

Giletti, A; Esperon, P. Genetic markers in methotrexate treatments. Pharmacogenomics 2018, 18(6), 689-703. doi.10.1038/s41397-018-0047-z DOI: https://doi.org/10.1038/s41397-018-0047-z

Schmiegelow, K. Advances in individual prediction of methotrexate toxicity: a review. Br. J. Haematol. 2009, 146(5), 489-503. doi.10.1111/j.1365-2141.2009.07765.x. DOI: https://doi.org/10.1111/j.1365-2141.2009.07765.x

Widemann, B.C.; Adamson, P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11(6), 694-703. doi.10.1634/theoncologist.11-6-694. DOI: https://doi.org/10.1634/theoncologist.11-6-694

Roche, B.; Clarke, P.A.; Collins Shaver, C.; Ford, D.; Thompson, J. High-Dose Methotrexate: Nursing Considerations for Administration and Supportive Care. Clin. J. Oncol. Nurs. 2023, 27(1), 47-54.

Ramsey, L.B.; Balis, F.M.; O'Brien, M.M.; Schmiegelow, K.; Pauley, J.L.; Bleyer, A.; Widemann, B.C.; Askenazi, D.; Bergeron, S.; Shirali, A.; Schwartz, S.; Vinks, A.A.; Heldrup, J. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 2018, 23(1), 52-61. doi.10.1634/theoncologist.2017-0243. DOI: https://doi.org/10.1634/theoncologist.2017-0243

Cronstein, B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 2005, 57(2), 163-72. doi.10.1124/pr.57.2.3 DOI: https://doi.org/10.1124/pr.57.2.3

Denburg, A.E.; Fundytus, A.; Khan, M.S.; Howard, S.C.; Antillon-Klussmann, F.; Sengar, M.; Lombe, D.; Hopman, W.; Jalink, M.; Gyawali, B.; Trapani, D.; Roitberg, F.; De Vries, E.G.E; Moja, L.; Ilbawi, A.; Sullivan, R.; Booth, C.M. Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Glob. Oncol. 2022, 8, At. No: e2200034. doi.10.1200/GO.22.00034. DOI: https://doi.org/10.1200/GO.22.00034

Sazonov, V.; Tobylbayeva, Z.; Saparov, A.; Jubaniyazov, B.; Issakov, S.; Gaipov, A. New Therapeutic Approach to Reduce Methotrexate Toxicity after High-Dose Chemotherapy in a Child with Acute Lymphocytic Leukemia: Efficacy and Safety of Hemoadsorption with HA-230 Adsorber. Blood Purif. 2022, 51(1), 91-95. doi.10.1159/000514135. DOI: https://doi.org/10.1159/000514135

Wright, K.D.; Panetta, J.C.; Onar-Thomas, A.; Reddick, W.E.; Patay, Z.; Qaddoumi, I.; Broniscer, A.; Robinson, G.; Boop, F.A.; Klimo, P.; Ward, D.; Gajjar, A.; Stewart, C,F. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother. Pharmacol. 2015, 75(1), 27-35. doi.10.1007/s00280-014-2614-6. DOI: https://doi.org/10.1007/s00280-014-2614-6

Widemann, B.C.; Balis, F.M.; Kim, A.; Boron, M.; Jayaprakash, N.; Shalabi, A.; O'Brien, M.; Eby, M.; Cole, D.E.; Murphy, R.F.; Fox, E.; Ivy, P.; Adamson, P.C. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J. Clin. Oncol. 2010, 28(25), 3979-86. doi.10.1200/JCO.2009.25.4540. DOI: https://doi.org/10.1200/JCO.2009.25.4540

Aleksandra Mikulska

mikulskaaleksandra3@gmail.com

Affiliation:

Students Scientific Association ‘’DRUG’’ in Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland Poland

Arkadiusz Kocur

arkadiusz.kocur@wum.edu.pl

Affiliation:

Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland Poland